← Back to Search

Immunosuppressant

Pirfenidone (PFD) for Systemic Scleroderma (SLSIII Trial)

Phase 2
Waitlist Available
Led By Michael D Roth, MD
Research Sponsored by Michael Roth
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
FVC-% of ≤85% at screening
Onset of the first non-Raynaud manifestation of SSc within the prior 84 months.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 months
Awards & highlights

SLSIII Trial Summary

This trial is testing a new treatment for scleroderma-related interstitial lung disease (SSc-ILD).

Eligible Conditions
  • Systemic Scleroderma
  • Interstitial Lung Disease

SLSIII Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

SLSIII Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent Predicted Forced Vital Capacity (FVC-%)
Other outcome measures
3.0% or Greater Improvement From Baseline in FVC-%.
Forced Vital Capacity Volume (FVC, in ml)
Greater Than 5% Improvement in FVC-%
+19 more

Side effects data

From 2022 Phase 2 trial • 51 Patients • NCT03221257
81%
Nausea
44%
Diarrhea
41%
Vomiting (Emesis)
30%
Fatigue
26%
Cough
22%
Headache
19%
Dizziness
15%
COVID-19
15%
Abdominal Pain
15%
Insomnia
11%
Anxiety
11%
Pruritis (Itching)
11%
Weight Loss
11%
Bloating
7%
Shortness of Breath
7%
Photosensitivity Reaction/Erythema
7%
Yeast Infection
7%
Upper Respiratory Tract Infection (URI)
7%
Depression
7%
Rash
7%
Gastro-esophageal Reflux Disease (GERD)
7%
Heartburn
7%
Loss of Appetite
7%
Tremors
7%
Joint Pain
7%
Sinusitis
7%
Myalgia
7%
Urinary Tract Infection (UTI)
7%
Back Pain
7%
Dysphagia
7%
Constipation
7%
ALT Increased
7%
Blood in Stool
7%
Loose Stools
7%
Stomach Pain
7%
Worsening GERD
4%
Herpes Zoster Ophthalmicus
4%
Right Sided Chest Pain
4%
Extra-nodal Marginal Zone B-cell Lymphoma of the Stomach and Antrum
4%
Scleroderma Renal Crisis
4%
Basal Cell Carcinoma, Nodular
4%
Dyspnea
4%
Leukopenia
4%
Upset Stomach
4%
Cold
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo (Plac) + Mycophenolate (MMF)
Pirfenidone (PFD) + Mycophenolate (MMF)

SLSIII Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Pirfenidone (PFD) + Mycophenolate (MMF)Experimental Treatment2 Interventions
Participants will receive Pirfenidone (PFD) as add-on to a background therapy of Mycophenolate Mofetil (MMF).
Group II: Placebo (Plac) + Mycophenolate (MMF)Placebo Group2 Interventions
Participants will receive Placebo (Plac) as add-on to a background therapy of Mycophenolate Mofetil (MMF).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pirfenidone (PFD)
2017
Completed Phase 2
~60
Mycophenolate Mofetil (MMF)
2000
Completed Phase 4
~690

Find a Location

Who is running the clinical trial?

University of MichiganOTHER
1,782 Previous Clinical Trials
6,364,606 Total Patients Enrolled
Genentech, Inc.Industry Sponsor
1,538 Previous Clinical Trials
567,629 Total Patients Enrolled
University of California, Los AngelesOTHER
1,521 Previous Clinical Trials
10,278,885 Total Patients Enrolled

Frequently Asked Questions

~7 spots leftby Mar 2025